TrialCancer research and treatment2024

Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.

Yoon-Koo Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.